Mode
Text Size
Log in / Sign up
N/A Completed N=1,280

Observational Non-Interventional Study With Spiriva Respimat in COPD Patients

Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT00699699 ↗
Enrolled (actual)
1,280
Serious AEs
0.5%
Results posted
Mar 2010
Primary outcomePrimary: Therapeutic Success as Change From Baseline in Physical Functioning After 6 Weeks — 61.5 Percentage of participants

Summary

This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients on treatment with Spiriva Respimat and allows adverse events to be recorded and evaluated.

Outcome Measures

OutcomeResultp-value
PRIMARY
Therapeutic Success as Change From Baseline in Physical Functioning After 6 Weeks
61.5 —
SECONDARY
Change From Baseline in the PF-10 Score After 6 Weeks
13.4 —
SECONDARY
Change From Baseline After 6 Weeks in Physician's Global Evaluation (PGE) Form Safety
1.1 —
SECONDARY
Patients' Satisfaction After 6 Weeks of Treatment
433; 551; 145; 77; 24; 21 —

Eligibility Criteria

Inclusion Criteria

COPD patients who require treatment with longacting anticholinergic

Exclusion Criteria

Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies. Spiriva® Respimat® is contraindicated in patients with hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to any of the excipients.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00699699). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search